Literature DB >> 19773083

Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.

Feng Chen, Lizhen Li, Daoxin Ma, Shuxin Yan, Jianzhi Sun, Maohong Zhang, Chunyan Ji, Ming Hou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19773083     DOI： 10.1016/j.leukres.2009.09.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  5 in total

1.  Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.

Authors:  Xinlai Cheng; Jee Young Kim; Shahrouz Ghafoory; Tijen Duvaci; Roya Rafiee; Jannick Theobald; Hamed Alborzinia; Pavlo Holenya; Johannes Fredebohm; Karl-Heinz Merz; Arianeb Mehrabi; Mohammadreza Hafezi; Arash Saffari; Gerhard Eisenbrand; Jörg D Hoheisel; Stefan Wölfl
Journal:  Mol Oncol       Date:  2016-02-04       Impact factor: 6.603

2.  Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.

Authors:  Nicolas Gaboriaud-Kolar; Vasillios Myrianthopoulos; Konstantina Vougogiannopoulou; Panagiotis Gerolymatos; David A Horne; Richard Jove; Emmanuel Mikros; Sangkil Nam; Alexios-Leandros Skaltsounis
Journal:  J Nat Prod       Date:  2016-10-11       Impact factor: 4.803

3.  Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2.

Authors:  Przemysław Czeleń; Beata Szefler
Journal:  J Mol Model       Date:  2015-03-10       Impact factor: 1.810

4.  Nanoscale isoindigo-carriers: self-assembly and tunable properties.

Authors:  Tatiana N Pashirova; Andrei V Bogdanov; Lenar I Musin; Julia K Voronina; Irek R Nizameev; Marsil K Kadirov; Vladimir F Mironov; Lucia Ya Zakharova; Shamil K Latypov; Oleg G Sinyashin
Journal:  Beilstein J Nanotechnol       Date:  2017-02-01       Impact factor: 3.649

Review 5.  Indirubin and Indirubin Derivatives for Counteracting Proliferative Diseases.

Authors:  Tina Blažević; Elke H Heiss; Atanas G Atanasov; Johannes M Breuss; Verena M Dirsch; Pavel Uhrin
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-17       Impact factor: 2.629
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.